Clinical Trial Update: Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 pivotal study results for iodine-131 tositumomab in chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin lymphoma; results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma
• Transformed Low-grade B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Iodine-131-tositumomab (Iodine-131-tositumomab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lymphoma, Non-Hodgkin | Phase 2 | Status: COMPLETED | Results posted: 2012-04-10